4D Molecular Therapeutics, Inc.
Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale countsTransaction codes
By Form 4 transaction code in selected period- M · Option exercise · dominant8 · 62%
- S · Open-market sells5 · 38%
Activity by reported role
A joint filing can contribute to multiple roles- CLO · dominant9 · 69%
- SR4 · 31%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (2)Reported Holdings After
Separated by insider, security, and ownership typeThese are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redTop insiders
By absolute net value across the selected period- KD-$881.3k
- BS-$30.4k
Recent filing activity
Most recent 12 transactions · color = transaction code- MOption exercise09/03$0SEC
- SSell09/03-$817kSEC
- MOption exercise09/03$379kSEC
- MOption exercise08/21$0SEC
- SSell08/21-$42.5MSEC
- SSell08/21-$66.2MSEC
- MOption exercise08/21$20.7MSEC
- MOption exercise08/17$0SEC
- MOption exercise08/17$0SEC
- SSell08/17-$1.99MSEC
- MOption exercise08/17$676kSEC
- SSell08/17-$1.96MSEC
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
FDMT transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| FDMT | Bizily Scott | CLO | exercise10b5-1 | 584 | $0 | M | — | 0.0% | 09/03 | 09/01 |
| FDMT | Bizily Scott | CLO | sale10b5-1 | 584 | -$817k | S | — | 0.0% | 09/03 | 09/01 |
| FDMT | Bizily Scott | CLO | exercise10b5-1 | 584 | $379k | M | — | 0.0% | 09/03 | 09/01 |
| FDMT | Kirn David | SR | exercise10b5-1 | 50.0k | $0 | M | −7.3% | 08/21 | 08/19 | |
| FDMT | Kirn David | SR | sale10b5-1 | 25.9k | -$42.5M | S | −7.3% | 08/21 | 08/19 | |
| FDMT | Kirn David | SR | sale10b5-1 | 43.1k | -$66.2M | S | −7.3% | 08/21 | 08/19 | |
| FDMT | Kirn David | SR | exercise10b5-1 | 50.0k | $20.7M | M | −7.3% | 08/21 | 08/19 | |
| FDMT | Bizily Scott | CLO | exercise10b5-1 | 1.63k | $0 | M | −1.3% | 08/17 | 08/17 | |
| FDMT | Bizily Scott | CLO | exercise10b5-1 | 1.63k | $0 | M | −1.3% | 08/17 | 08/13 | |
| FDMT | Bizily Scott | CLO | sale10b5-1 | 1.63k | -$1.99M | S | −1.3% | 08/17 | 08/17 | |
| FDMT | Bizily Scott | CLO | exercise10b5-1 | 1.63k | $676k | M | −1.3% | 08/17 | 08/17 | |
| FDMT | Bizily Scott | CLO | sale10b5-1 | 1.63k | -$1.96M | S | −1.3% | 08/17 | 08/13 | |
| FDMT | Bizily Scott | CLO | exercise10b5-1 | 1.63k | $676k | M | −1.3% | 08/17 | 08/13 |
4D Molecular Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at 4D Molecular Therapeutics, Inc.?
Bizily Scott, Kirn David.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Bizily Scott reported a sale on Sep 01, 2026 valued at $817k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $1,136,016.27. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.